Results 61 to 70 of about 390,971 (277)
International Forum of Allergy &Rhinology, EarlyView.Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Eric R. Ramos +7 more
wiley +1 more source
Quality Advantage? Provider Quality and Networks in Medicare Advantage
Journal of Public and Nonprofit Affairs, 2020 Medicare Advantage plans have grown significantly over the past decade and the potential for their future growth seems unabated. Astonishingly, however, we know little about how Medicare beneficiaries access services, particularly whether those services ...
Simon F. Haeder
doaj +1 more source
Low-Income Subsidies for the Medicare Prescription Drug Benefit: The Impact of the Asset Test [PDF]
, 2005 Assesses the impact of the requirement that low-income individuals with Medicare meet an asset test in order to receive additional help paying premiums and cost sharing under the new Medicare drug benefit.
Katherine A. Desmond, Thomas Rice
core
Annals of Neurology, EarlyView.Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono +3 more
wiley +1 more source
Fork in the Road: Alternative Paths to a High Performance U.S. Health System [PDF]
, 2009 Estimates the cost savings and coverage rates of three options for healthcare reform: an insurance exchange with no public plan, a public plan paying Medicare rates, and a public plan paying rates midway between Medicare and private plan ...
Cathy Schoen +3 more
core
Annals of Neurology, EarlyView.Objective To evaluate the real‐world safety and efficacy for standard surgical risk patients with extracranial internal carotid artery disease undergoing transcarotid artery revascularization. Methods ROADSTER 3 is a prospective, multicenter, single‐arm post‐approval study.
Jeffrey Jim +15 more
wiley +1 more source
"Income-related patient cost-sharing: Simulation for prescription drugs under Medicare" [PDF]
This paper studies an application of income-related patient cost-sharing. Using data from the Medicare Current Beneficiary Survey, we find that varying patient costsharing rates with patient income in the Medicare prescription drug program can reduce the
Kenneth A. Lewis, Laurence S. Seidman
core
Arthritis &Rheumatology, EarlyView.Objectives Growing evidence suggests farming and agricultural pesticide use may be associated with rheumatoid arthritis (RA), but few studies have examined specific pesticides and RA among women living on farms, who may personally use pesticides or may be indirectly exposed.
Christine G. Parks +7 more
wiley +1 more source
Federal Employees Health Benefits Program (FEHBP): Available Health Insurance Options [PDF]
, 2012 FEHBP is generally available to employees, annuitants, and their dependents. Eligible individuals may elect coverage in an approved health benefits plan for either individual or family coverage.
Mach, Annie L
core +3 more sources
Arthritis &Rheumatology, EarlyView.Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih +3 more
wiley +1 more source